Galenea is a biotechnology company committed to improving the quality of life for people with central nervous system diseases. The company was founded in 2003 based upon research from the Massachusetts Institute of Technology and Rockefeller University. Through our unique access to proprietary technology, animal models and human genetic analysis, our scientists are engaging in cutting-edge research for the development of novel treatments for psychiatric diseases with a focus on schizophrenia. By employing sophisticated preclinical models at an early stage of candidate development, we can select compounds that have the best chance of clinical and commercial success. Our business model is to develop and license early stage technologies and to advance them to Phase II proof-of-concept studies at which stage they can be further developed through partnerships with global pharmaceutical companies. At Galenea, we foster a vibrant, interactive, and collaborative scientific and business environment and consider career growth and development a high priority.

Click here to see pictures of our new facilities at 300 Technology Square in Cambridge, MA.